RFK Jr.’s new vaccine panel raises questions of conflicts

The new panel, which has its own entanglements, will meet for the first time later this month.

June 13, 2025 Check out STAT+

Sponsored By

Michael Ciaglo/Getty Images STAT+ | RFK Jr.'s new vaccine panel raises questions of how Kennedy defines conflicts of interest Kennedy fired ACIP vaccine panel over pharma ties, but new members' own conflicts, vaccine skepticism raise fresh public health questions. By Chelsea Cirruzzo STAT+ | In fight over research overhead funding, universities propose alternatives to Trump's cuts Facing NIH indirect cost cuts, universities float new funding models for research overhead, seeking policy fixes to protect labs, federal grants. By Jonathan Wosen The life-and-death stakes of RFK Jr.'s decision to remake a vaccine panel What's more, the health secretary's ACIP move could signal that more changes are coming — and the consequences could be dire. By Matthew Herper Adobe STAT+ | Opinion: Recursion CEO: Biotech's rainy season is not over — but we must race ahead With capital drying up and market tailwinds gone, the biotech industry — including Recursion — needs to make tactical decisions. By Chris Gibson STAT+ | A vaccine expert explains why she's 'very worried' about RFK Jr. and new CDC vaccine advisers Vaccine expert Kathryn Edwards tells STAT's Readout LOUD podcast that under HHS Secretary Kennedy, "our entire vaccine infrastructure could crumble." By Adam Feuerstein and Elaine Chen STAT+ | Feds greenlight $9 billion in supplemental Medicaid funds as GOP weighs new limits States race to secure billions in Medicaid funding before Congress caps future deals, as new federal rules and GOP tax plans threaten provider payments. By Bob Herman Misha Friedman/Getty Images STAT+ | Opinion: Don't cut NIH and NSF budgets — let the government invest like a venture capitalist Bayh-Dole should be repealed so the government can retain a share of IP generated through NIH and NSF grants. By Sahand Hormoz FDA clears Moderna's RSV vaccine for use in people aged 18 to 59 Previously, the vaccine, mResvia, was licensed for people 60 and older. Next up: Will CDC vaccine experts' recommendation for adults 50 to 59 be endorsed? By Helen Branswell

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser